Ling-Hsien Tu

Prof. Ling-Hsien Tu

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2014 in Nature Chemistry
Verified
Journal Article
Open access
PDF file
LYLydia M. Young
Lydia M. Young
JSJanet C. Saunders
Janet C. Saunders
RMRachel A. Mahood
Rachel A. Mahood
CRCharlotte H. Revill
Charlotte H. Revill
RFRichard J. Foster
Richard J. Foster
AAAlison E. Ashcroft
Alison E. Ashcroft
The search for therapeutic agents that bind specifically to precursor protein conformations and inhibit amyloid assembly is an important challenge. Identifying such inhibitors is difficult because many protein precursors of aggregation are partially folded or intrinsically disordered, which rules out structure-based design. Furthermore, inhibitors can act by a variety of mechanisms, including specific or nonspecific binding, as well as colloidal inhibition. Here we report a high-throughput method based on ion mobility spectrometry–mass spectrometry (IMS–MS) that is capable of rapidly detecting small molecules that bind to amyloid precursors, identifying the interacting protein species and defining the mode of inhibition. Using this method we have classified a variety of small molecules that are potential inhibitors of human islet amyloid polypeptide (hIAPP) aggregation or amyloid-beta 1-40 aggregation as specific, nonspecific, colloidal or non-interacting. We also demonstrate the ability of IMS–MS to screen for inhibitory small molecules in a 96-well plate format and use this to discover a new inhibitor of hIAPP amyloid assembly.

15 November 2015 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
RARehana Akter
Rehana Akter
PCPing Cao
Ping Cao
HNHarris Noor
Harris Noor
ZRZachary Ridgway
Zachary Ridgway
LTLing-Hsien Tu
Ling-Hsien Tu
DRDaniel P. Raleigh
Daniel P. Raleigh
The hormone islet amyloid polypeptide (IAPP, or amylin) plays a role in glucose homeostasis but aggregates to form islet amyloid in type-2 diabetes. Islet amyloid formation contributes toβ-cell dysfunction and death in the disease and to the failure of islet transplants. Recent work suggests a role for IAPP aggregation in cardiovascular complications of type-2 diabetes and hints at a possible role in type-1 diabetes. The mechanisms of IAPP amyloid formationin vivoorin vitroare not understood and the mechanisms of IAPP inducedβ-cell death are not fully defined. Activation of the inflammasome, defects in autophagy, ER stress, generation of reactive oxygen species, membrane disruption, and receptor mediated mechanisms have all been proposed to play a role. Open questions in the field include the relative importance of the various mechanisms ofβ-cell death, the relevance of reductionist biophysical studies to the situationin vivo, the molecular mechanism of amyloid formationin vitroandin vivo, the factors which trigger amyloid formation in type-2 diabetes, the potential role of IAPP in type-1 diabetes, the development of clinically relevant inhibitors of islet amyloidosis toxicity, and the design of soluble, bioactive variants of IAPP for use as adjuncts to insulin therapy.

1 February 2013 in FEBS Letters
Verified
Journal Article
Open access
PCPing Cao
Ping Cao
PMPeter Marek
Peter Marek
HNHarris Noor
Harris Noor
VPVadim Patsalo
Vadim Patsalo
LTLing-Hsien Tu
Ling-Hsien Tu
DRDaniel P. Raleigh
Daniel P. Raleigh
Pancreatic islet amyloid is a characteristic feature of type 2 diabetes. The major protein component of islet amyloid is the polypeptide hormone known as islet amyloid polypeptide (IAPP, or amylin). IAPP is stored with insulin in the β‐cell secretory granules and is released in response to the stimuli that lead to insulin secretion. IAPP is normally soluble and is natively unfolded in its monomeric state, but forms islet amyloid in type 2 diabetes. Islet amyloid is not the cause of type 2 diabetes, but it leads to β‐cell dysfunction and cell death, and contributes to the failure of islet cell transplantation. The mechanism of IAPP amyloid formation is not understood and the mechanisms of cytotoxicity are not fully defined.

23 May 2016 in eLife
Verified
Journal Article
Open access
AAAndisheh Abedini
Andisheh Abedini
APAnnette Plesner
Annette Plesner
PCPing Cao
Ping Cao
ZRZachary Ridgway
Zachary Ridgway
JZJinghua Zhang
Jinghua Zhang
ASAnn Marie Schmidt
Ann Marie Schmidt
Islet amyloidosis by IAPP contributes to pancreatic β-cell death in diabetes, but the nature of toxic IAPP species remains elusive. Using concurrent time-resolved biophysical and biological measurements, we define the toxic species produced during IAPP amyloid formation and link their properties to induction of rat INS-1 β-cell and murine islet toxicity. These globally flexible, low order oligomers upregulate pro-inflammatory markers and induce reactive oxygen species. They do not bind 1-anilnonaphthalene-8-sulphonic acid and lack extensive β-sheet structure. Aromatic interactions modulate, but are not required for toxicity. Not all IAPP oligomers are toxic; toxicity depends on their partially structured conformational states. Some anti-amyloid agents paradoxically prolong cytotoxicity by prolonging the lifetime of the toxic species. The data highlight the distinguishing properties of toxic IAPP oligomers and the common features that they share with toxic species reported for other amyloidogenic polypeptides, providing information for rational drug design to treat IAPP induced β-cell death.

11 November 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
PCPing Cao
Ping Cao
AAAndisheh Abedini
Andisheh Abedini
HWHui Wang
Hui Wang
LTLing-Hsien Tu
Ling-Hsien Tu
XZXiaoxue Zhang
Xiaoxue Zhang
DRDaniel P. Raleigh
Daniel P. Raleigh
Islet amyloid polypeptide (IAPP) is responsible for amyloid formation in type 2 diabetes and contributes to the failure of islet cell transplants, however the mechanisms of IAPP-induced cytotoxicity are not known. Interactions with model anionic membranes are known to catalyze IAPP amyloid formation in vitro. Human IAPP damages anionic membranes, promoting vesicle leakage, but the features that control IAPP–membrane interactions and the connection with cellular toxicity are not clear. Kinetic studies with wild-type IAPP and IAPP mutants demonstrate that membrane leakage is induced by prefibrillar IAPP species and continues over the course of amyloid formation, correlating additional membrane disruption with fibril growth. Analyses of a set of designed mutants reveal that membrane leakage does not require the formation of β-sheet or α-helical structures. A His-18 to Arg substitution enhances leakage, whereas replacement of all of the aromatic residues via a triple leucine mutant has no effect. Biophysical measurements in conjunction with cytotoxicity studies show that nonamyloidogenic rat IAPP is as effective as human IAPP at disrupting standard anionic model membranes under conditions where rat IAPP does not induce cellular toxicity. Similar results are obtained with more complex model membranes, including ternary systems that contain cholesterol and are capable of forming lipid rafts. A designed point mutant, I26P-IAPP; a designed double mutant, G24P, I26P-IAPP; a double N-methylated variant; and pramlintide, a US Food and Drug Administration–approved IAPP variant all induce membrane leakage, but are not cytotoxic, showing that there is no one-to-one relationship between disruption of model membranes and induction of cellular toxicity. Significance Amyloid formation is a hallmark of a range of human diseases. The polypeptide hormone amylin forms amyloid deposits in type 2 diabetes, and amyloid formation is thought to be a contributor to the decline in β-cell mass in the disease, however the basis of amylin-induced cytotoxicity is not fully understood. Amylin-induced membrane disruption has attracted considerable interest, and the interactions of amylin with model membranes have been characterized, but the relationship between studies with model membranes and toxicity is not understood. In this article the relationship between cell toxicity and the ability to disrupt model membranes is examined. There is no direct correlation between the two processes.

20 December 2012 in Biochemistry
Verified
Journal Article
Closed access
LTLing-Hsien Tu
Ling-Hsien Tu
DRDaniel P. Raleigh
Daniel P. Raleigh